Podcasts - theheart.org : Thoughts and opinions on cardiology news

Hormone therapy and MI; Durata, Riata ST Optim lead analysis; no benefit of fish oil; long-term PROTECT-AF analysis

info@theheart.org (theheart.org) — Fri, 17 May 2013 12:50:00 EDT

Hormone therapy and MI; Durata, Riata ST Optim lead analysis; no benefit of fish oil; long-term PROTECT-AF analysis

Stem-cell therapy for hypoplastic left heart syndrome

info@theheart.org (theheart.org) — Tue, 14 May 2013 14:00:00 EDT

After showing promising results in early-phase trials for ischemic heart disease, stem-cell therapy is now being examined as a possible mechanism to treat congenital diseases such as hyperplastic left heart syndrome.

ESC on anticoagulants; FDA on Liptruzet; Midei suit; MitraClip

info@theheart.org (theheart.org) — Fri, 10 May 2013 11:55:00 EDT

ESC on anticoagulants; FDA approves atorvastatin/ezetimibe combo (Liptruzet) ; Midei suit settled; MitraClip

Vitamin D; cardiologists' pay; intestinal flora; Kcentra

info@theheart.org (theheart.org) — Fri, 03 May 2013 16:00:00 EDT

Vitamin D; cardiologists' pay; intestinal flora; Kcentra

Canagliflozin; PURE; low-glycemic and Mediterranean diets

info@theheart.org (theheart.org) — Fri, 26 Apr 2013 11:55:00 EDT

Canagliflozin; PURE; low-glycemic and Mediterranean diets

#29: What's different about heart disease in women?

info@theheart.org (theheart.org) — Mon, 22 Apr 2013 16:15:00 EDT

After years of being omitted from clinical trials, research is finally taking strides to recognize the specificity of heart disease in women. Dr Sharon Mulvagh joins Dr Bernard Gersh to ask why wouldn't there be differences in heart disease between women

#187: Beet this: More evidence of BP-lowering effects of dietary nitrate; amiodarone-cancer link reemerges in observational study; ACE inhibitor, beta-blocker may thwart cardiotoxicity from chemotherapy; will new FDA meeting on Avandia prompt withdrawal?

info@theheart.org (theheart.org) — Fri, 19 Apr 2013 12:55:00 EDT

Beet this: More evidence of BP-lowering effects of dietary nitrate; amiodarone-cancer link reemerges in observational study; ACE inhibitor, beta-blocker may thwart cardiotoxicity from chemotherapy; will new FDA meeting on Avandia prompt withdrawal o

#186: Prasugrel noninferior to ticagrelor, but both achieve poor platelet inhibition at two hours; REVIVEd in print: REVIVE levosimendan trials finally get peer-review validation; nonsystem issues prolong door-to-balloon times, up mortality in primary PCI

info@theheart.org (theheart.org) — Fri, 12 Apr 2013 16:55:00 EDT

Prasugrel noninferior to ticagrelor, but both achieve poor platelet inhibition at two hours; REVIVEd in print: REVIVE levosimendan trials finally get peer-review validation; nonsystem issues prolong door-to-balloon times, up mortality in primary PCI

#57: Incentivizing adherence with Drs Steve Driver and Don Hensrud

info@theheart.org (theheart.org) — Fri, 26 Apr 2013 16:50:00 EDT

Patient adherence-as recently demonstrated in the MI FREE trial-is a notoriously complicated issue that is the focus of several ongoing research projects. Drs Steve Driver and Don Hensrud join the show to discuss their innovative trial presented at ACC

#28: Cardiac device infections: From A to Z

info@theheart.org (theheart.org) — Mon, 08 Apr 2013 09:25:00 EDT

Despite the ever shrinking size of devices and our greater technical expertise, there has been a disproportionate rise in the rate infections associated with cardiac devices. Drs Raul Espinosa and M Rizwan Sohail join Dr Charanjit (Chet) Rihal to discuss

#185: Carvedilol superior to metoprolol in MADIT-CRT analysis; FDA approves new diabetes drug, canagliflozin, despite CV concerns; heart-smart diabetes drugs; more beaches, less bureaucracy, say burned out cardiologists

info@theheart.org (theheart.org) — Fri, 05 Apr 2013 16:15:00 EDT

Carvedilol superior to metoprolol in MADIT-CRT analysis; FDA approves new diabetes drug, canagliflozin, despite CV concerns; heart-smart diabetes drugs; more beaches, less bureaucracy, say burned out cardiologists

#184: Rivaroxaban gets ACS indication recommendation from European regulators; MitraClip narrowly passes major test with FDA advisory panel; new oral anticoagulants in secondary stroke prevention: Apples and oranges?; EMA recommends restricting cilostazol

info@theheart.org (theheart.org) — Thu, 28 Mar 2013 14:25:00 EDT

Rivaroxaban gets ACS indication recommendation from European regulators; MitraClip narrowly passes major test with FDA advisory panel; new oral anticoagulants in secondary stroke prevention: Apples and oranges?; EMA recommends restricting cilostazol

#183: Mixed messages on new bleeding data with dabigatran; "high-potency" statins linked to acute kidney injury; dabigatran might cut hospital days vs standard anticoagulants in new AF; US supermarket chain giving away atorvastatin

info@theheart.org (theheart.org) — Fri, 22 Mar 2013 12:25:00 EDT

Mixed messages on new bleeding data with dabigatran; "high-potency" statins linked to acute kidney injury; dabigatran might cut hospital days vs standard anticoagulants in new AF; US supermarket chain giving away atorvastatin

#27: Heart transplantation: Selecting the ideal candidate

info@theheart.org (theheart.org) — Thu, 21 Mar 2013 11:35:00 EDT

Which patients are the best candidates for heart transplantation? Drs Sudhir Kushwaha and Rocky Daly-respectively the medical and surgical directors of the Heart Transplantation and VAD therapy program at Mayo Clinic-review the steps to selecting patient

#56: Talking fat with Dr Roger Blumenthal

info@theheart.org (theheart.org) — Wed, 20 Mar 2013 11:15:00 EDT

With an ever-growing percentage of the population either overweight or obese, the topic of staying trim is a matter of international proportions.

#182: ACC 2013: Stopping rivaroxaban and warfarin temporarily in AF patients yields similar risks; PREVAIL yanked from ACC program; Watchman device meets safety end point; Niacin full results in HPS2-THRIVE; Another strike for digoxin in AF

info@theheart.org (theheart.org) — Wed, 13 Mar 2013 19:00:00 EDT

ACC 2013: Stopping rivaroxaban and warfarin temporarily in AF patients yields similar risks; PREVAIL yanked from ACC program; Watchman device meets safety end point; Niacin full results in HPS2-THRIVE; Another strike for digoxin in AF

#181: What's going to be hot at ACC 2013; rivaroxaban STEMI study hits print as FDA delivers setback; Watchman ups quality of life vs chronic warfarin in nonvalvular AF; FDA again seeks more info on rivaroxaban in ACS

info@theheart.org (theheart.org) — Thu, 07 Mar 2013 12:12:00 EST

What's going to be hot at ACC 2013; rivaroxaban STEMI study hits print as FDA delivers setback; Watchman ups quality of life vs chronic warfarin in nonvalvular AF; FDA again seeks more info on rivaroxaban in ACS

#180: "Choosing wisely" now targets over 130 dubious tests, therapies; HPS2-THRIVE: High myopathy risk with niacin/laropiprant; unrestricted Mediterranean diets beat low-fat advice for primary CVD prevention; large proportion of raised LDL cholesterol...

info@theheart.org (theheart.org) — Fri, 01 Mar 2013 14:30:00 EST

Choosing wisely now targets over 130 dubious tests, therapies; HPS2-THRIVE: High myopathy risk with niacin/laropiprant; unrestricted Mediterranean diets beat low-fat advice for primary CVD prevention; large proportion of raised LDL cholesterol in

#26: A sign of the times: Social media's impact on SCAD research

info@theheart.org (theheart.org) — Mon, 25 Feb 2013 18:15:00 EST

Research on spontaneous coronary artery dissection (SCAD) at the Mayo Clinic is a telling example of "patient-initiated" research made possible by social media. Dr Sharonne Hayes discusses with Dr Sharon Mulvagh the genesis of the SCAD project and the...

#179: NJ cardiologist received more than $100 000 in referral kickbacks; deaths doubled with high calcium intake plus supplements; widely used diclofenac associated with increased risk of CV events; functional evaluation of CAD using angiographic images

info@theheart.org (theheart.org) — Fri, 22 Feb 2013 10:50:00 EST

NJ cardiologist received more than $100 000 in referral kickbacks; deaths doubled with high calcium intake plus supplements; widely used diclofenac associated with increased risk of CV events; functional evaluation of CAD using angiographic images alone

#178: Short course of aspirin, clopidogrel cuts stroke risk; Lp(a) gene variant associated with aortic stenosis; MAGELLAN published: Rivaroxaban reduces VTE risk in acutely ill patients; weight-loss drug Qsymia improves cardiovascular risk profile

info@theheart.org (theheart.org) — Fri, 15 Feb 2013 13:25:00 EST

course of aspirin, clopidogrel cuts stroke risk; Lp(a) gene variant associated with aortic stenosis; MAGELLAN published: Rivaroxaban reduces VTE risk in acutely ill patients; weight-loss drug Qsymia improves cardiovascular risk profile

#25: Preventing AF: The role of ACE inhibitors and ARBs

info@theheart.org (theheart.org) — Thu, 14 Feb 2013 21:45:00 EST

Popular treatment options fail to recognize AF as a consequence of other problems and instead attempt to treat atrial fibrillation as if it were the problem itself.

#55: Practicing humanism in medicine with Dr Abraham Verghese

info@theheart.org (theheart.org) — Wed, 13 Feb 2013 14:15:00 EST

Renowned author and internist Dr Abraham Verghese joins Dr Bob Harrington to consider the role of humanism in medical practice and the joy of sharing effective tools for patient care. We can cure patients, but how good are we at helping them to heal?

#177: Runner who died during London Marathon took stimulant DMAA during race; weight-loss myths refuted in new review; new AHA/ASA guidelines for acute stroke treatment; slight risk of QT-interval prolongation found with two antidepressants

info@theheart.org (theheart.org) — Fri, 08 Feb 2013 10:25:00 EST

Dead London Marathon runner took stimulant DMAA during race; weight-loss myths refuted in new review; new AHA/ASA guidelines for acute stroke treatment; slight risk of QT-interval prolongation found with two antidepressants

#176: No benefit to dual RAS blockade in meta-analysis; metabolic syndrome in 40s linked to TV, lack of exercise, at age 16; Canadian Riata experience: Electrical failures eclipse externalized cables; "napkin-ring sign" on CT identifies high-risk coronary

info@theheart.org (theheart.org) — Fri, 01 Feb 2013 10:45:00 EST

No benefit to dual RAS blockade in meta-analysis; Metabolic syndrome in 40s linked to TV, lack of exercise, at age 16; Canadian Riata experience: Electrical failures eclipse externalized cables; "Napkin-ring sign" on CT identifies high-risk coronary

#24: The epidemiology of heart failure

info@theheart.org (theheart.org) — Wed, 30 Jan 2013 15:30:00 EST

Dr Veronique Roger joins Dr Bernard Gersh to review the latest data and share insight into what is now termed an epidemic.

#175: Apixaban approved: Now, which anticoagulant to use?; darbepoetin alfa disappoints in RED-HF; suspect thrombus with signs of early valve degeneration after TAVI; half of cardiology practices now integrated with hospitals

info@theheart.org (theheart.org) — Fri, 25 Jan 2013 11:20:00 EST

Apixaban approved: Now, which anticoagulant to use?; darbepoetin alfa disappoints in RED-HF; suspect thrombus with signs of early valve degeneration after TAVI; half of cardiology practices now integrated with hospitals

#23: Valve repair: Who, where, why

info@theheart.org (theheart.org) — Thu, 24 Jan 2013 11:50:00 EST

Dr Vuyisile Nkomo is joined by Dr Joseph Dearani for an update on the latest information pertaining to surgical valve repair.

#174: Niacin/laropiprant products to be suspended; JNC 8, ATP 4 guidelines; new meta-analysis on sugar sparks old debate; two antihypertensives plus NSAID ups risk of acute kidney injury

info@theheart.org (theheart.org) — Fri, 18 Jan 2013 14:50:00 EST

Niacin/laropiprant products to be suspended; JNC 8, ATP 4 guidelines; new meta-analysis on sugar sparks old debate; two antihypertensives plus NSAID ups risk of acute kidney injury

#22: Getting to the root of the problem: Thoracic and endovascular surgery

info@theheart.org (theheart.org) — Fri, 11 Jan 2013 14:50:00 EST

What's the latest on the surgical treatment of thoracic aortic disease? Dr Juan Bowen catches up with Dr Alberto Pochettino on issues such as safety of surgical procedures and when to refer a patient for surgery...

#173: Exercise woefully underutilized; lesser degrees of excess weight don't increase mortality; FDA approves apixaban for stroke prevention in nonvalvular AF; fructose intake may contribute to overeating

info@theheart.org (theheart.org) — Fri, 11 Jan 2013 14:40:00 EST

Exercise woefully underutilized; lesser degrees of excess weight don't increase mortality; FDA approves apixaban for stroke prevention in nonvalvular AF; fructose intake may contribute to overeating

#54: Current state of surgical revascularization in patients with CAD with Dr Timothy Gardner

info@theheart.org (theheart.org) — Tue, 08 Jan 2013 10:00:00 EST

The FREEDOM trial has added a wealth of data to the debate on revascularization in patients with heart disease. Dr Timothy Gardner joins the show to discuss the revascularization options, what we have learned from FREEDOM, BARI, BARI 2D, and PREVENT ...

#172: Biggest stories of 2012; AHA top-10 list; think you might have AF? There's an app for that; some diabetic patients may be overtreated with high-dose statins

info@theheart.org (theheart.org) — Fri, 21 Dec 2012 15:35:00 EST

Biggest stories of 2012; AHA top-10 list; think you might have AF? There's an app for that; some diabetic patients may be overtreated with high-dose statins

#21: When congenital heart disease grows up

info@theheart.org (theheart.org) — Fri, 21 Dec 2012 12:00:00 EST

Thanks to important improvements in care, more than 85% of people with congenital heart disease are surviving well into adulthood. What is the best method to continue caring for these patients?

#20: The changing face of acute MI

info@theheart.org (theheart.org) — Tue, 18 Dec 2012 00:00:00 EST

Trends in the US (and the developed world) point to a radical change in the patterns of acute MI—as shown by both a decrease in CV mortality and STEMI.

#171: Dabigatran: Reassuring data on major bleeds; ACCOMPLISH BMI analysis doesn't mean obese hypertensives should get diuretics; AMPLIFY-EXT on apixaban in risk of long-term recurrent-VTE; aggressive smoking cessation; hands-only CPR/defibrillation

info@theheart.org (theheart.org) — Fri, 14 Dec 2012 15:25:00 EST

Dabigatran: Reassuring data on major bleeds; ACCOMPLISH BMI analysis doesn't mean obese hypertensives should get diuretics; AMPLIFY-EXT on apixaban in risk of long-term recurrent-VTE; aggressive smoking cessation; hands-only CPR/defibrillation in out-of-h

#170: SCAI releases new consensus on "ad hoc" PCI; societies prepare interventionalists for new payment codes; heart-healthy diet additive to drug benefits in secondary prevention; increased mortality with digoxin in AF; warfarin for six months should be

info@theheart.org (theheart.org) — Fri, 14 Dec 2012 00:00:00 EST

SCAI releases new consensus on "ad hoc" PCI; societies prepare interventionalists for new payment codes; heart-healthy diet additive to drug benefits in secondary prevention; increased mortality with digoxin in AF; warfarin for six months should be

#169: Pall cast on Durata ICD lead as FDA document made public; "holistic" analysis shows domino effect of TAVI risk factors; CT coronary angiography identifies significant plaques in "normal" arteries; major bleeds with warfarin in AF are often fatal;

info@theheart.org (theheart.org) — Fri, 30 Nov 2012 00:00:00 EST

Pall cast on Durata ICD lead as FDA document made public; "holistic" analysis shows domino effect of TAVI risk factors; CT coronary angiography identifies significant plaques in "normal" arteries; major bleeds with warfarin in AF are often fatal; low seru

#19: The hormonal dilemma: Unraveling an "acute confusional state"

info@theheart.org (theheart.org) — Wed, 28 Nov 2012 00:00:00 EST

Where do things stand with hormone-replacement therapy? Dr Sharon Mulvagh joins Dr Bernard Gersh to shine light on the notoriously complicated data—including the HERS, WHI, KEEPS, and DOPS trials—and show why the trial results are not as contradictory as

#168: Diabetes risk outweighed by CV benefit of statins; "threshold" effect for vitamin D and CVD: New meta-analysis; European approvals for apixaban in AF, rivaroxaban for PE/DVT; New guidelines emphasize OMT for stable IHD; FDA approves HeartWare VAD

info@theheart.org (theheart.org) — Fri, 23 Nov 2012 00:00:00 EST

Diabetes risk outweighed by CV benefit of statins; "threshold" effect for vitamin D and CVD: New meta-analysis; European approvals for apixaban in AF, rivaroxaban for PE/DVT; New guidelines emphasize OMT for stable IHD; FDA approves HeartWare VAD fo

#53: Beta blockers in stable heart disease with Dr Sripal Bangalore

info@theheart.org (theheart.org) — Tue, 20 Nov 2012 00:00:00 EST

Despite cautious and limited guideline endorsement, beta blockers are widely used in cardiovascular disease (and beyond). Why? Our guest Dr Sripal Bangalore discusses his research, which caused a stir in CV spheres but actually does not differ greatly fro

#167: Dabigatran looks good long term: RELY-ABLE; occasional cocaine use can do acute and chronic damage; MADIT-RIT: Simple programming change averts most inappropriate ICD therapy; BLOCK-HF: Replace

info@theheart.org (theheart.org) — Fri, 16 Nov 2012 00:00:00 EST

Dabigatran looks good long term: RELY-ABLE; occasional cocaine use can do acute and chronic damage; MADIT-RIT: Simple programming change averts most inappropriate ICD therapy; lipid profiles: Fasting not necessary, concludes study; BLOCK-HF: Replace RV p

#18: Radiofrequency ablation in AF

info@theheart.org (theheart.org) — Tue, 13 Nov 2012 16:25:00 EST

Despite years of research, our understanding of this field remains limited. Dr Douglas Packer joins the show to discuss the pathophysiology of atrial fibrillation in regard to the targets for radiofrequency ablation, how the procedure has changed in the p

#166: CABG superior to PCI in diabetics in FREEDOM; impressive antihypertensive effect of flaxseed; what role for PFO closure?; TACT: Surprising, puzzling benefit from chelation therapy after MI; TRILOGY/ARCTIC: Back to the drawing board for platelet moni

info@theheart.org (theheart.org) — Fri, 09 Nov 2012 12:20:00 EST

CABG superior to PCI in diabetics in FREEDOM; impressive antihypertensive effect of flaxseed; what role for PFO closure?; TACT: Surprising, puzzling benefit from chelation therapy after MI; TRILOGY/ARCTIC: Back to the drawing board for platelet monitoring

#165: What's hot at AHA 2012; PFO-closure trials RESPECT and PC miss primary end point; prasugrel bests clopidogrel in TRILOGY-ACS angiography cohort; RIVAL: Major benefits with radial PCI in STEMI vs NSTEMI; RF ablation, antiarrhythmic meds comparable as

info@theheart.org (theheart.org) — Fri, 02 Nov 2012 18:30:00 EDT

What's hot at AHA 2012; PFO-closure trials RESPECT and PC miss primary end point; prasugrel bests clopidogrel in TRILOGY-ACS angiography cohort; RIVAL: Major benefits with radial PCI in STEMI vs NSTEMI; RF ablation, antiarrhythmic meds comparable as

#12: Are patients best served by reporting, transparency, and appropriate-use criteria?

info@theheart.org (theheart.org) — Tue, 30 Oct 2012 16:05:00 EDT

Recent ruminations on public reporting (of PCI) generally conclude with the notion that patient outcomes are better in states that report. Right? Not according to Dr Paul Teirstein, who offers his cath-lab experience in California and New York to present

#164: In diabetics, lifestyle management fails to reduce hard CV outcomes: Look AHEAD halted; rivaroxaban okayed for PE in Europe; PFO closure trials take spotlight at TCT 2012; small increased risk of CV events with diclofenac; FDA expands Sapien TAVI in

info@theheart.org (theheart.org) — Fri, 26 Oct 2012 13:30:00 EDT

In diabetics, lifestyle management fails to reduce hard CV outcomes: Look AHEAD halted; rivaroxaban okayed for PE in Europe; PFO closure trials take spotlight at TCT 2012; small increased risk of CV events with diclofenac; FDA expands Sapien TAVI in

#17: Treating ventricular tachycardia in patients without structural heart disease

info@theheart.org (theheart.org) — Wed, 24 Oct 2012 09:35:00 EDT

Dr Bernard Gersh asks Dr Samuel Asirvatham about the syndromes that categorize patients who have ventricular tachycardia in the absence of structural heart disease and what the treatment options—including ablation—are for these patients.

#163: HRT cuts CVD by 50%, latest "unique" data show; WSJ: St Jude knew of Riata lead flaws at end of 2005; MIST investigator accused of false data; pacemaker implants with CoreValve edge lower; NHANES: Lipid levels improve across US over 20 years

info@theheart.org (theheart.org) — Fri, 19 Oct 2012 13:45:00 EDT

HRT cuts CVD by 50%, latest "unique" data show; WSJ: St Jude knew of Riata lead flaws at end of 2005; MIST investigator accused of false data; pacemaker implants with CoreValve edge lower; NHANES: Lipid levels improve across US over 20 years

#52: Patient adherence and drug discontinuation with Dr Niteesh Choudhry

info@theheart.org (theheart.org) — Wed, 17 Oct 2012 14:30:00 EDT

A combination of many issues—such as misunderstanding the importance of medications, forgetfulness, finances, and more complex social factors—patient nonadherence to drug therapy is a major public concern and an impediment to global health.

#2: Policies to address cardiovascular disease in India with Dr Srinath Reddy

info@theheart.org (theheart.org) — Mon, 15 Oct 2012 16:20:00 EDT

Now that the risk to health from noncommunicable diseases is being taken very seriously, what action is the government taking to contain cardiovascular disease in India?

#162: Beta blockers of no use in stable CAD; docs debate valve choice; Montreal cardiologist suspended; adherence to warfarin-adjustment algorithm sharpens anticoagulation: RE-LY; CV risk prediction: CRP, fibrinogen add modestly

info@theheart.org (theheart.org) — Fri, 12 Oct 2012 09:00:00 EDT

Beta blockers of no use in stable CAD; docs debate valve choice; Montreal cardiologist suspended; adherence to warfarin-adjustment algorithm sharpens anticoagulation: RE-LY; CV risk prediction: CRP, fibrinogen add modestly

#16: LVAD therapy for patients with congestive heart failure

info@theheart.org (theheart.org) — Wed, 10 Oct 2012 14:45:00 EDT

Guest host Dr Margaret Redfield discusses the basics of left ventricular assist devices (LVADs)—as bridge to transplant, destination therapy, and bridge to recovery—with leading heart-failure surgeon Dr Soon Park. What role are LVADs playing in HF?

#161: Single-drug polypharmacy; dabigatran use climbing in US; consistent benefit of apixaban: ARISTOTLE; sulfonylurea cardiotoxicity probed; Bonhoeffer to be struck off medical register

info@theheart.org (theheart.org) — Fri, 05 Oct 2012 14:45:00 EDT

Single-drug polypharmacy; dabigatran use climbing in US; consistent benefit of apixaban: ARISTOTLE; sulfonylurea cardiotoxicity probed; Bonhoeffer to be struck off medical register

#15: Healthcare reform--All doom and gloom?

info@theheart.org (theheart.org) — Fri, 28 Sep 2012 11:20:00 EDT

In the context of shrinking funds and an aging population (10 000 people turn 65 each day), what is the status of healthcare reform in the US? Guest host Dr Chet Rihal catches up with Dr Ray Gibbons for a frank discussion on where things stand, what ...

#160: Statins and diabetes risk: More data; clopidogrel poststenting: The case for shorter duration, interruptions; EMA supports apixaban for AF/stroke; statins do not reduce the risk of VTE: New meta-analysis; rethinking routine testing of chest-pain pat

info@theheart.org (theheart.org) — Fri, 28 Sep 2012 16:40:00 EDT

Statins and diabetes risk: More data; clopidogrel poststenting: The case for shorter duration, interruptions; EMA supports apixaban for AF/stroke; statins do not reduce the risk of VTE: New meta-analysis; rethinking routine testing of chest-pain patients

#159: Renal denervation cost-effective for resistant hypertension; no CV benefit of omega-3 fatty acids: Meta-analysis; doing nothing about CVD will cost $47 trillion; decline in nuclear tests per patient; restless legs linked to CHD

info@theheart.org (theheart.org) — Fri, 21 Sep 2012 14:10:00 EDT

Renal denervation cost-effective for resistant hypertension; no CV benefit of omega-3 fatty acids: Meta-analysis; doing nothing about CVD will cost $47 trillion; decline in nuclear tests per patient; restless legs linked to CHD

#158: NSAID risk persists five years post-MI; Obesity paradox strengthened by new SCAAR data in ACS; RELY finds dabigatran bleeding-related gene variant; Antihypertensive use in pregnancy up; Door-to-activation times drives PCI delays

info@theheart.org (theheart.org) — Fri, 14 Sep 2012 14:18:00 EDT

Published each Friday, this podcast delivers the week's five most popular articles in audio format. Stay on top of the latest cardiology news, wherever your week takes you.

#51: Stem-cell therapy in cardiovascular medicine: An update with Dr Bobby Robbins

info@theheart.org (theheart.org) — Mon, 10 Sep 2012 16:15:00 EDT

Regenerative therapy using stem cells has—for a long time—shown great potential to impact cardiovascular medicine. What's the current state of the field?

#14: Sudden cardiac death in the young: The role of arrhythmogenic right ventricular dysplasia

info@theheart.org (theheart.org) — Fri, 07 Sep 2012 12:00:00 EDT

Sudden cardiac death in the young: The role of arrhythmogenic right ventricular dysplasia

#157: Chocolate reduces stroke risk in men; RE-LY Registry: Wide global variation in AF management, mortality; apixaban for AF patients with renal dysfunction?; CDC: US losing war against hypertension; ATLAS ACS 2 TIMI 51: 2.5-mg rivaroxaban cuts cardiac

info@theheart.org (theheart.org) — Fri, 07 Sep 2012 13:40:00 EDT

Chocolate reduces stroke risk in men; RE-LY Registry: Wide global variation in AF management, mortality; apixaban for AF patients with renal dysfunction?; CDC: US losing war against hypertension; ATLAS ACS 2 TIMI 51: 2.5-mg rivaroxaban cuts cardiac events

#156: Results from ESC 2012; TRILOGY ACS: No win for prasugrel; WOEST: Drop aspirin in stent patients on oral anticoagulants; ALTITUDE: New data on why trial halted; PARAMOUNT phase 2; IABP SHOCK II; New European STEMI guidelines; HPS2-THRIVE

info@theheart.org (theheart.org) — Fri, 31 Aug 2012 12:00:00 EDT

Results from ESC 2012; TRILOGY ACS: No win for prasugrel; WOEST: Drop aspirin in stent patients on oral anticoagulants; ALTITUDE: New data on why trial halted; PARAMOUNT phase 2: Agent shows promise in preserved-EF HF; IABP SHOCK II: No survival benefit o

#13: Hemodynamic subsets in aortic stenosis: It's not so simple

info@theheart.org (theheart.org) — Sun, 26 Aug 2012 10:45:00 EDT

Mayo Clinic cardiovascular fellow Dr Mackram Eleid joins Dr Bernard Gersh to discuss his research on the complicated subject of low flow, low gradient aortic stenosis, and particularly why it's important to examine the disease as systemic, involving the a

#155: ESC 2012: What's going to be hot; MIST investigator charges Circulation, AHA, with "breaking their own rules" on disclosure; FDA: Get X-rays of Riata lead; Meta-analysis challenges drug use in mild hypertension; PINNACLE-AF: slow uptake of new antic

info@theheart.org (theheart.org) — Fri, 24 Aug 2012 08:30:00 EDT

ESC 2012: What's going to be hot; MIST investigator charges Circulation, AHA, with "breaking their own rules" on disclosure; FDA: Get X-rays of Riata lead; Meta-analysis challenges drug use in mild hypertension; PINNACLE-AF: slow uptake of new antic

#154: JUPITER analysis on diabetes risk with statins; statins linked to cataracts; chocolate nudges down BP in meta-analysis; bleeding risk tools compared in AF; troponin algorithm rules MI in or out in 77% of chest-pain patients

info@theheart.org (theheart.org) — Fri, 17 Aug 2012 11:20:00 EDT

JUPITER analysis on diabetes risk with statins; statins linked to cataracts; chocolate nudges down BP in meta-analysis; bleeding risk tools compared in AF; troponin algorithm rules MI in or out in 77% of chest-pain patients

#153: AHA/ASA advisory on stroke prevention in AF; possible dabigatran, rivaroxaban antidotes; lip-cancer risk raised by photosensitizing antihypertensives; paper disputes MI count in TRITON, RECORD, and PLATO; US government investigates HCA hospitals

info@theheart.org (theheart.org) — Fri, 10 Aug 2012 12:55:00 EDT

AHA/ASA advisory on stroke prevention in AF; possible dabigatran, rivaroxaban antidotes work in vitro in human blood; lip-cancer risk raised by photosensitizing antihypertensives; paper disputes MI count in TRITON, RECORD, and PLATO; US government i

#12: What's new in constrictive pericarditis with Dr Jae Oh

info@theheart.org (theheart.org) — Wed, 08 Aug 2012 16:00:00 EDT

Dr Bernard Gersh is joined by Dr Jae Oh, professor of medicine and director of cardiac imaging and the pericardial diseases clinic at Mayo Clinic, to review the diagnostic evaluation of patients with constriction vs restriction.

#50: Biomarkers: Past, present, future with Dr Jim Januzzi

info@theheart.org (theheart.org) — Tue, 07 Aug 2012 22:10:00 EDT

Biomarkers: Past, present, future with Dr Jim Januzzi

#152: Even nonobstructive CAD at CT predicts risk in symptomatic patients: CONFIRM; FDA approves EPA-only omega-3 PUFA capsule; Aggressive heart-rate control reduces radiation from CCTA; rivaroxaban gets NICE thumbs-up for DVT; BMJ: TAVI is overused

info@theheart.org (theheart.org) — Fri, 03 Aug 2012 14:30:00 EDT

#152: Even nonobstructive CAD at CT predicts risk in symptomatic patients: CONFIRM; FDA approves EPA-only omega-3 PUFA capsule; Aggressive heart-rate control reduces radiation from CCTA; rivaroxaban gets NICE thumbs-up for DVT; BMJ analysis: TAVI is vastl

#151: London 2012: Preventing SCD; CT-based FFR saves money by reducing PCIs; polypill for primary prevention: largest-yet reductions in BP, cholesterol in small trial; job stress strains women's hearts; workplace solvents linked to heart defects

info@theheart.org (theheart.org) — Fri, 27 Jul 2012 14:00:00 EDT

London 2012: Preventing sudden cardiac death; CT-based FFR saves money by reducing PCIs; polypill for primary prevention: largest-yet reductions in BP, cholesterol in small trial; job stress strains women's hearts; workplace solvents linked to heart ...

#11: Controversies in ICD implantation

info@theheart.org (theheart.org) — Wed, 25 Jul 2012 16:00:00 EDT

Despite a significant body of trial data supporting the implantation of ICDs for secondary and primary prevention, controversies persist. Dr Paul Friedman joins Dr Bernard Gersh to discuss the issues that cloud patient selection and how to cope with ICD..

#1: The burden of heart disease in India in 2012 with Dr Rajeev Gupta

info@theheart.org (theheart.org) — Thu, 26 Jul 2012 16:20:00 EDT

In this inaugural episode, host Dr Denis Xavier and renowned academic Dr Rajeev Gupta set the stage for the series with an overview of heart disease in India and its underlying risk factors.

#150: Higher HDL-particle concentrations associated with reduced CHD risk; HRT ups BP; risk of hypertension higher with longer duration of use; journal publishes spoof on AUC; "weekend effect" in stroke study; FDA approves new diet drug

info@theheart.org (theheart.org) — Fri, 20 Jul 2012 13:10:00 EDT

Higher HDL-particle concentrations associated with reduced CHD risk; HRT ups BP; risk of hypertension higher with longer duration of use; journal publishes spoof on appropriate-use criteria; "weekend effect" in stroke study; FDA approves new diet dr

#149: Apixaban delay prompts "not-us!" chorus; tighter UK food policies could slash CV deaths; echo vs nuclear for stress imaging after revascularization; NCDR registry: Many getting DES would do as well with BMS; ticagrelor tops prasugrel in pharmacodyna

info@theheart.org (theheart.org) — Fri, 13 Jul 2012 14:45:00 EDT

Apixaban delay prompts "not-us!" chorus; tighter UK food policies could slash CV deaths; Echo vs nuclear for stress imaging after revascularization; NCDR registry: Many getting DES would do as well with BMS; ticagrelor tops prasugrel in pharmacodynamic...

#10: Novel anticoagulants in AF: An overview of the latest data with Dr Robert McBane

info@theheart.org (theheart.org) — Wed, 11 Jul 2012 08:30:00 EDT

The past year has brought an embarrassment of riches in the realm of anticoagulation for patients with atrial fibrillation, as dabigatran, rivaroxaban, and apixaban vie to compete with warfarin.

#148: EVINCI: Invasive diagnostic tests can be dramatically reduced; cardiologists react to Supreme Court decision on ACA; readmission rates after MI not the best quality indicator?; rosiglitazone in healthcare-fraud case; 10-minute echo in young athlete

info@theheart.org (theheart.org) — Fri, 06 Jul 2012 11:50:00 EDT

EVINCI: Invasive diagnostic tests can be dramatically reduced; cardiologists react to Supreme Court decision on ACA; readmission rates after MI not the best quality indicator?; rosiglitazone in healthcare-fraud case; 10-minute echo in young athlete

#49: The pros and cons of being a cardiologist in 2012 with Dr Seth Bilazarian

info@theheart.org (theheart.org) — Wed, 04 Jul 2012 10:45:00 EDT

Private practitioner and theheart.org blogger Dr Seth Bilazarian joins the show to discuss the pros and cons of cardiology in 2012 and express what continues to make his practice enjoyable and fulfilling (despite it all).

#147: No US approval yet for apixaban for stroke prevention in atrial fibrillation; FDA approves lorcaserin for the treatment of obesity; FDA refuses ACS indication for rivaroxaban—for now; Are statins less effective in women?

info@theheart.org (theheart.org) — Fri, 29 Jun 2012 13:36:00 EDT

Published each Friday, this podcast delivers the week's five most popular articles in audio format. Stay on top of the latest cardiology news, wherever your week takes you.

#146: Stem-cell findings strike at long-held vascular disease dogma; multibiomarker test for predicting CVD; Measuring apolipoproteins does not help risk prediction; First-in-human transcatheter mitral-valve implant

info@theheart.org (theheart.org) — Fri, 22 Jun 2012 14:10:00 EDT

Stem-cell findings strike at long-held vascular disease dogma; multibiomarker test for predicting CVD; Measuring apolipoproteins does not help risk prediction; First-in-human transcatheter mitral-valve implant

#9: Novel insights into Marfan syndrome: Diagnostics, pathophysiology, and treatment with Dr Charles Bruce

info@theheart.org (theheart.org) — Tue, 26 Jun 2012 09:30:00 EDT

The longevity of people with Marfan syndrome has dramatically improved in the past years thanks to improved diagnostics, pharmacological management, and timely intervention.

#145: Mortality benefit of running less than 20 miles per week; label update for dabigatran; who gets published?; alcohol may trigger AF episodes; FDA advisors: approve Sapien TAVR for high-risk operable patients

info@theheart.org (theheart.org) — Fri, 15 Jun 2012 11:45:00 EDT

Mortality benefit of running less than 20 miles per week; label update for dabigatran; who gets published?; alcohol may trigger AF episodes; FDA advisors: approve Sapien TAVR for high-risk operable patients

#8: Options for the nonrevascularizable patient with Dr Amir Lerman

info@theheart.org (theheart.org) — Wed, 13 Jun 2012 10:55:00 EDT

Options for the nonrevascularizable patient with Dr Amir Lerman

#144: Exercise worsens a CV risk factor in 10% of people; don't give up on HDL, researchers plead; major bleeding with aspirin in primary prevention underestimated; dietary calcium better than supplements; more evidence dark chocolate is cardioprotective

info@theheart.org (theheart.org) — Fri, 08 Jun 2012 10:40:00 EDT

Exercise worsens a CV risk factor in 10% of people; don't give up on HDL, researchers plead; major bleeding with aspirin in primary prevention underestimated; dietary calcium better than supplements; more evidence dark chocolate is cardioprotective

#20: Asking the right questions in fellowship, training, and academic medicine with Drs Chris O'Connor and Tariq Ahmad

info@theheart.org (theheart.org) — Tue, 05 Jun 2012 11:40:00 EDT

Asking the right questions in fellowship, training, and academic medicine with Drs Chris O'Connor and Tariq Ahmad

#143: Dabigatran fatal bleeding less than in trials; obesity paradox in ACCOMPLISH; dulaglutide passes BP hurdle; DIG revisited: digoxin scrutinized anew; LDL-receptor mAb: more impressive data

info@theheart.org (theheart.org) — Fri, 01 Jun 2012 12:00:00 EDT

Dabigatran fatal bleeding less than in trials; obesity paradox in ACCOMPLISH; dulaglutide passes BP hurdle; DIG revisited: digoxin scrutinized anew; LDL-receptor mAb: more impressive data

#7: New guidelines for hypertrophic cardiomyopathy with Dr Bernard Gersh

info@theheart.org (theheart.org) — Wed, 30 May 2012 10:15:00 EDT

New guidelines for hypertrophic cardiomyopathy with Dr Bernard Gersh

#142: Statins benefit those at much lower CV risk; so long, Plavix; ARISTOTLE: Apixaban cuts stroke risk in all types of AF; Next-generation transcatheter aortic valve looks good; 2012 European HF guidelines

info@theheart.org (theheart.org) — Fri, 25 May 2012 12:15:00 EDT

Statins benefit those at much lower CV risk; so long, Plavix; ARISTOTLE: Apixaban cuts stroke risk in all types of AF; Next-generation transcatheter aortic valve looks good; 2012 European HF guidelines

#48: Focus on novel anticoagulants in clinical practice with Dr Elaine Hylek

info@theheart.org (theheart.org) — Fri, 25 May 2012 03:40:00 EDT

Cardiologists now have a wealth of choice for anticoagulation, but with competitors to warfarin crowding the physician's office, it's increasingly difficult to select the most appropriate agent for patients with atrial fibrillation.

#141: Pfizer stops promoting Lipitor in US; moderate coffee intake protects against stroke; MagnaSafe: MRI with pacers, ICDs: Safe, a few minor issues; FAME II: FFR pinpoints stable CAD patients who do worse with OMT; whistleblower suit implicates Nissen

info@theheart.org (theheart.org) — Fri, 18 May 2012 11:35:00 EDT

Pfizer stops promoting Lipitor in US; moderate coffee intake protects against stroke; MagnaSafe: MRI with pacers, ICDs: Safe, a few minor issues; FAME II: FFR pinpoints stable CAD patients who fare worse with OMT; whistleblower suit implicates Nissen, Cle

#6: What's new in acute pericarditis with Dr Jae Oh

info@theheart.org (theheart.org) — Thu, 17 May 2012 11:00:00 EDT

Dr Jae Oh, professor of medicine and director of cardiac imaging and the pericardial diseases clinic at Mayo, joins Dr Bernard Gersh for an update on the latest on acute pericarditis.

#140: Ideal blood-pressure goals? "We have no idea"; more adverse events seen on dabigatran vs warfarin; WHF defends Dubai WCC, reimburses Israelis denied visas; Roche stops dalcetrapib trial; bypass moderate coronary lesions? taking sides in the debate

info@theheart.org (theheart.org) — Fri, 11 May 2012 11:40:00 EDT

Ideal blood-pressure goals? "We have no idea"; more adverse events seen on dabigatran vs warfarin; WHF defends Dubai WCC, reimburses Israelis denied visas; Roche stops dalcetrapib trial; bypass moderate coronary lesions? taking sides in the debate

#139: CHA2DS2-VASc score gives best prediction of stroke risk in AF; subcutaneous ICD: thumbs up from FDA; DES or bare-metal stents for primary PCI?; beware valve involvement in device-related infective endocarditis; CMS restricts TAVI coverage to experie

info@theheart.org (theheart.org) — Fri, 04 May 2012 13:40:00 EDT

CHA2DS2-VASc score gives best prediction of stroke risk in AF; subcutaneous ICD: thumbs up from FDA; DES or bare-metal stents for primary PCI?; beware valve involvement in device-related infective endocarditis; CMS restricts TAVI coverage to experie

#5: Diagnosis and treatment of heart failure with preserved ejection fraction (HFPEF) with Dr Barry Borlaug

info@theheart.org (theheart.org) — Fri, 04 May 2012 05:20:00 EDT

Dr Bernard Gersh talks to Dr Barry Borlaug about the intricacies of diagnosis and treatment of heart failure with preserved ejection fraction (HFPEF), traditionally known as diastolic heart failure.

#138: FDA: No aliskiren with ACE inhibitors, ARBs in some patients; cardiologists: high income, many frustrations; TIPS 2 on full-dose polypill; ESC paper on new anticoagulants; Bahrain AED survey points to CPR barriers

info@theheart.org (theheart.org) — Fri, 27 Apr 2012 13:00:00 EDT

FDA: No aliskiren with ACE inhibitors, ARBs in some patients; cardiologists: high income, many frustrations; TIPS 2 on full-dose polypill; ESC paper on new anticoagulants; Bahrain AED survey points to CPR barriers

#4: Genetic heart-rhythm diseases with Dr Michael Ackerman

info@theheart.org (theheart.org) — Thu, 19 Apr 2012 11:50:00 EDT

Dr Michael Ackerman, professor of medicine, pediatrics, and pharmacology, with a particular interest in cardiac arrhythmias, joins the show to discuss heritable arrhythmia syndromes.

#137: Big bonuses for cardiologists at OSU; higher glycated hemoglobin levels, better outcomes in HF with diabetes; losartan vs candesartan mortality risk in HF disputed; Italian soccer player dies on the pitch; Maryland to set up independent PCI review

info@theheart.org (theheart.org) — Fri, 20 Apr 2012 15:00:00 EDT

Big bonuses for cardiologists at OSU; higher glycated hemoglobin levels, better outcomes in HF with diabetes; losartan vs candesartan mortality risk in HF disputed; Italian soccer player dies on the pitch; Maryland to establish independent review fo

#136: COURAGE angle for NY analysis of PCI vs meds in stable CAD; many left ventriculographies are unnecessary; persistent high cholesterol more likely in countries with poorer healthcare; statins in primary prevention

info@theheart.org (theheart.org) — Fri, 13 Apr 2012 12:17:00 EDT

Published each Friday, this podcast delivers the week's five most popular articles in audio format. Stay on top of the latest cardiology news, wherever your week takes you.

#47: Rebooting the medical system with Dr Eric Topol

info@theheart.org (theheart.org) — Wed, 11 Apr 2012 15:45:00 EDT

Technology is the key to a radical transformation of medicine, which is shifting from a population-based model to one of individualization. Will cardiologists and medical practitioners be left behind?

#3: Implementing TAVI in the community with Dr David Holmes

info@theheart.org (theheart.org) — Thu, 05 Apr 2012 15:45:00 EDT

What are the best methods for implementing TAVI? What can we learn from the adoption of TAVI in Europe? Dr David Holmes, immediate past president of the American College of Cardiology, discusses his thoughts with Dr Bernard Gersh.

#135: Analysis extends dabigatran MI signal to other thrombin inhibitors; new oral anticoagulants in AF: What to do in clinical practice; Riata ICD lead failures: Short-circuit risk; "statins for all"; biodegradable-polymer DES: Solid four-year safety and

info@theheart.org (theheart.org) — Thu, 05 Apr 2012 14:00:00 EDT

Analysis extends dabigatran MI signal to other thrombin inhibitors; new oral anticoagulants in AF: What to do in clinical practice; Riata ICD lead failures: Short-circuit risk; "statins for all"; biodegradable-polymer DES: Solid four-year safety and

#134: Vorapaxar in TRA 2°P-TIMI 50; response time key in renal-denervation; rivaroxaban in EINSTEIN PE; levels of LDL cholesterol predate cancer cases; ASCERT CABG, PCI analysis; Canadian AF guidelines

info@theheart.org (theheart.org) — Fri, 30 Mar 2012 11:25:00 EDT

Vorapaxar in TRA 2°P-TIMI 50; response time key in renal-denervation; rivaroxaban in EINSTEIN PE; levels of LDL cholesterol predate cancer cases; ASCERT CABG, PCI analysis; Canadian AF guidelines

#133: What's hot at ACC 2012; CLOSURE I published; few Americans achieve "ideal" CV health; varespladib phase 3 ACS trial halted early; life and community on an LVAD

info@theheart.org (theheart.org) — Fri, 23 Mar 2012 17:30:00 EDT

What's hot at ACC 2012; CLOSURE I published; few Americans achieve "ideal" CV health; varespladib phase 3 ACS trial halted early; life and community on an LVAD

#132: "Real-world" analysis: New anticoagulants better than warfarin in AF; PTCA pioneer passes away: Dr Geoffrey Hartzler; Florida stem-cell cardiologist has license suspended; Dabigatran cost-effective vs warfarin; theheart.org's statin safety survey

info@theheart.org (theheart.org) — Fri, 16 Mar 2012 14:30:00 EDT

"Real-world" analysis: New anticoagulants better than warfarin in AF; PTCA pioneer passes away: Dr Geoffrey Hartzler; Florida stem-cell cardiologist has license suspended; Dabigatran cost-effective vs warfarin; theheart.org's statin safety survey

#46: Healthcare reform and cardiovascular practice in the election year with Dr Kevin Schulman

info@theheart.org (theheart.org) — Thu, 15 Mar 2012 16:30:00 EDT

Where do things stand with healthcare reform? What is the status of CMS innovation centers, accountable care models (ACOs), and new models for reimbursement?

#2: Cardiac cell repair therapy with Dr Robert Simari

info@theheart.org (theheart.org) — Wed, 14 Mar 2012 09:29:00 EDT

Cardiac stem-cell research has come a long way, offering new insights into cardiac cell repair therapy.

#1: Cardiology today: Science, education, and practice with ACC president Dr David Holmes

info@theheart.org (theheart.org) — Wed, 14 Mar 2012 09:22:00 EDT

What's the pulse of cardiology today? American College of Cardiology president Dr David Holmes talks to Dr Bernard Gersh about the past year in cardiology—addressing the challenges of practice, education and learning, reimbursement, and appropriateness cr

#131: Details help explain dabigatran bleeds in New Zealand; FDA moves on rivaroxaban and apixaban; ivabradine front-page UK news; TAVR program how-to; renal denervation and cardiac function

info@theheart.org (theheart.org) — Fri, 09 Mar 2012 15:55:00 EST

Details help explain dabigatran bleeds in New Zealand; FDA moves on rivaroxaban and apixaban; ivabradine front-page UK news; TAVR program how-to; renal denervation and cardiac function

#130: FDA adds warnings to statin label; nine brain-cancer cases in interventionalists; why cardiac death risk is highest in early morning: discovery; Predictors of ICH include warfarin treatment; no mortality or MI benefit in stable CAD patients treated

info@theheart.org (theheart.org) — Fri, 02 Mar 2012 15:15:00 EST

FDA adds warnings to statin label; nine brain-cancer cases in interventionalists; why cardiac death risk is highest in early morning: discovery; Predictors of ICH include warfarin treatment; no mortality or MI benefit in stable CAD patients treated

#129: ACCP thrombosis guidelines on aspirin in primary prevention; EMA on aliskiren, aprotinin, and orlistat; homocysteine saga: is gene analysis the final chapter?; FDA advisors recommend approval of obesity drug Qnexa; guideline-recommended HF therapies

info@theheart.org (theheart.org) — Fri, 24 Feb 2012 10:40:00 EST

ACCP thrombosis guidelines on aspirin in primary prevention; EMA on aliskiren, aprotinin, and orlistat; homocysteine saga: is gene analysis the final chapter?; FDA advisors recommend approval of obesity drug Qnexa; guideline-recommended HF therapies

#128: Factor Xa reversal: More hope; criticism of PCI appropriateness criteria; Mediator scandal in France: Over 1300 deaths; Indian echo project takes remote diagnosis global

info@theheart.org (theheart.org) — Fri, 17 Feb 2012 14:15:00 EST

Factor Xa reversal: More hope; criticism of PCI appropriateness criteria; Mediator scandal in France: Over 1300 deaths; Indian echo project takes remote diagnosis global

#11: Planes, mains, and flying machines

info@theheart.org (theheart.org) — Tue, 14 Feb 2012 10:05:00 EST

What parallels can we draw between practicing cardiology and piloting airplanes?

#45: Clopidogrel pharmacogenomics: Challenges, controversies, and clinical implications with Dr Jessica Mega

info@theheart.org (theheart.org) — Fri, 10 Feb 2012 14:35:00 EST

Clopidogrel pharmacogenomics: Challenges, controversies, and clinical implications with Dr Jessica Mega

#127: Wine and chocolate: Flavonoid and polyphenol research; clopidogrel plus aspirin: No benefit for stroke prevention; wireless power delivery for LVADs; TRA 2°P: Vorapaxar meets end point but ups bleeding

info@theheart.org (theheart.org) — Fri, 10 Feb 2012 14:00:00 EST

Wine and chocolate: Flavonoid and polyphenol research; clopidogrel plus aspirin: No benefit for stroke prevention; wireless power delivery for LVADs; TRA 2°P: Vorapaxar meets end point but ups bleeding

#126: Patient care concerns ignored, careers destroyed, claim docs; heart attack deaths plummet in three EU nations; "valve-on-a-stick" transaortic TAVI alternative to transfemoral; Vytorin US label updated; risk begins with middle-age risk factors

info@theheart.org (theheart.org) — Fri, 03 Feb 2012 15:50:00 EST

Patient care concerns ignored, careers destroyed, claim docs; heart attack deaths plummet in three EU nations; "valve-on-a-stick" transaortic TAVI alternative to transfemoral; Vytorin US label updated; risk begins with middle-age risk factors

#125: Cardiologists accused of defrauding Medicare; treat risk and not LDL-cholesterol targets; PLATO: PPI analysis "raises flag"; "recalled" Riata ICD leads: summit aims for guidance; statins: to prescribe or not to prescribe?

info@theheart.org (theheart.org) — Fri, 27 Jan 2012 13:30:00 EST

Cardiologists accused of defrauding Medicare; treat risk and not LDL-cholesterol targets; PLATO: PPI analysis "raises flag"; "recalled" Riata ICD leads: summit aims for guidance; statins: to prescribe or not to prescribe?

#124: Resveratrol researchers on Das fraud scandal; BRIDGE study published; US bleeding ADRs: dabigatran vs warfarin; statins: four times more costly in US than UK; dronedarone gets another chance in combo trial

info@theheart.org (theheart.org) — Fri, 20 Jan 2012 14:50:00 EST

Resveratrol researchers on Das fraud scandal; BRIDGE study published; US bleeding ADRs: dabigatran vs warfarin; statins: four times more costly in US than UK; dronedarone gets another chance in combo trial

#123: Obesity: Focus on excess calories; Informed consent in patient's death after stem-cell treatment; Dabigatran: New data on MI and ischemic events; Serum potassium targets in acute MI; RESPECT PFO/stroke trial completes enrollment

info@theheart.org (theheart.org) — Fri, 13 Jan 2012 17:00:00 EST

Obesity: Focus on excess calories; Informed consent in patient's death after stem-cell treatment; Dabigatran: New data on MI and ischemic events; Serum potassium targets in acute MI; RESPECT PFO/stroke trial completes enrollment

#44: Improving patient adherence to medication with Dr Eric Peterson

info@theheart.org (theheart.org) — Mon, 09 Jan 2012 15:45:00 EST

Patient adherence to medication has long defied quantification, with many physicians assuming that the cost of medications is the primary factor explaining poor rates of compliance. How do we explain abysmal rates of patient adherence to medication?

#121: Vitamin D fails again to affect CV mortality; more overstenting charges in Maryland; data show antihypertensive therapy prolongs life; ALTITUDE halted; RECOVER II on benefit of dabigatran in treatment of VTE

info@theheart.org (theheart.org) — Fri, 23 Dec 2011 11:45:00 EST

Vitamin D fails again to affect CV mortality; more overstenting charges in Maryland; data show antihypertensive therapy prolongs life; ALTITUDE halted; RECOVER II on benefit of dabigatran in treatment of VTE

#122: Top news in 2011--Apixaban win in ARISTOTLE; the heart can repair itself; dalcetrapib passes test in dal-VESSEL; FDA restricts simvastatin 80 mg; NIH stops AIM-HIGH; poor long-term outcomes post ablation of AF; caution with dabigatran in elderly; FD

info@theheart.org (theheart.org) — Thu, 29 Dec 2011 13:40:00 EST

Top news in 2011--Apixaban win in ARISTOTLE; the heart can repair itself; dalcetrapib passes test in dal-VESSEL; FDA restricts simvastatin 80 mg; NIH stops AIM-HIGH; poor long-term outcomes post ablation of AF; caution with dabigatran in elderly; FDA

#120: CardioMEMS implantable PA-pressure monitor rejected by FDA; iPad app streams real-time data; bleeding in AF: European consensus; concern over Pfizer's Lipitor deals; cardiologists support elective PCI without on-site CABG: Survey

info@theheart.org (theheart.org) — Fri, 16 Dec 2011 13:35:00 EST

CardioMEMS implantable PA-pressure monitor rejected by FDA; iPad app streams real-time data; bleeding in AF: European consensus; concern over Pfizer's Lipitor deals; cardiologists support elective PCI without on-site CABG: Survey

#119: Stents, ICDs, inappropriate? Then CMS won't pay; FDA investigating serious bleeding events with dabigatran; Generic atorvastatin now in US; CV risk negligible with COX-2 inhibitors but AF a possible concern; noncardiac chest pain

info@theheart.org (theheart.org) — Fri, 09 Dec 2011 14:50:00 EST

Stents, ICDs, inappropriate? Then CMS won't pay; FDA investigating serious bleeding events with dabigatran; Generic atorvastatin now in US; CV risk negligible with COX-2 inhibitors but AF a possible concern; noncardiac chest pain

#43: Same-day discharge from the hospital after elective PCI with Dr Sunil Rao

info@theheart.org (theheart.org) — Wed, 07 Dec 2011 14:30:00 EST

What is the best way to care for patients following PCI? Is same-day discharge a viable—or even desirable—option? Dr Sunil Rao joins the show to discuss his recent paper in JAMA, including the background for the study, source of data, and methodology.

#118: CONFIRM CT registry raises more questions; CHADS2 predicts AF problems; Batting Big Tobacco; 30-day readmissions following PCI

info@theheart.org (theheart.org) — Fri, 02 Dec 2011 14:21:00 EST

Published each Friday, this podcast delivers the week's five most popular articles in audio format. Stay on top of the latest cardiology news, wherever your week takes you.

#117: Dabigatran fatal bleeds; Vitamin D; Sodium J-curve; Erasmus MC fires Poldermans; postshock driving restrictions

info@theheart.org (theheart.org) — Fri, 25 Nov 2011 15:40:00 EST

Dabigatran fatal bleeds; Vitamin D; Sodium J-curve; Erasmus MC fires Poldermans; postshock driving restrictions

#116: "Bridging" anticoagulation may not be necessary in many; AIM-HIGH: Results raise controversy; ATLAS ACS 2: Low-dose rivaroxaban looks good; SATURN trial; US dabigatran label updated; FDA on fenofibrate

info@theheart.org (theheart.org) — Fri, 18 Nov 2011 13:45:00 EST

"Bridging" anticoagulation may not be necessary in many; AIM-HIGH: Results raise controversy; ATLAS ACS 2: Low-dose rivaroxaban looks good; SATURN trial; US dabigatran label updated; FDA on fenofibrate

#10: What case for live cases?

info@theheart.org (theheart.org) — Mon, 14 Nov 2011 09:35:00 EST

From the floor of the TCT convention center, Drs Eric Topol and Paul Teirstein ponder live cases: immoral grandstanding or important learning and treatment opportunity?

#115: What's going to be hot at AHA; FDA approves rivaroxaban; FDA issues "safety communication" on fenofibrate; Study backs ACE inhibitors, ARBs for aortic regurgitation; AHA/ACCF hypertrophic cardiomyopathy guidelines

info@theheart.org (theheart.org) — Fri, 11 Nov 2011 15:00:00 EST

What's going to be hot at AHA; FDA approves rivaroxaban; FDA issues "safety communication" on fenofibrate; Study backs ACE inhibitors, ARBs for aortic regurgitation; AHA/ACCF hypertrophic cardiomyopathy guidelines

#114: Cardiologist, are you fat, unfit, unmotivated?; BP meds more effective at night; FDA advisors recommend Vytorin; fludrocortisone flops for vasovagal syncope; FDA recommends Sapien valve

info@theheart.org (theheart.org) — Fri, 04 Nov 2011 15:45:00 EDT

Cardiologist, are you fat, unfit, unmotivated?; BP meds more effective at night; FDA advisors recommend Vytorin; fludrocortisone flops for vasovagal syncope; FDA recommends Sapien valve

#42: Statins--Cardiovascular benefit vs diabetes risk with Dr Michael Cobble

info@theheart.org (theheart.org) — Tue, 01 Nov 2011 10:35:00 EDT

Statins have become a cornerstone therapy in the prevention of cardiovascular disease by helping to modify the risk profile of millions of people. But what about a possible connection between statin use and diabetes?

#113: Public Citizen on rivaroxaban; More registry data on Sapien and CoreValve; Endeavor and DAPT; PARADIGM on aspirin in primary prevention; Little consensus on CAD extent, severity

info@theheart.org (theheart.org) — Fri, 28 Oct 2011 14:40:00 EDT

Public Citizen on rivaroxaban; More registry data on Sapien and CoreValve; Endeavor and DAPT; PARADIGM on aspirin in primary prevention; Little consensus on CAD extent, severity

#112: Heart-failure hospitalizations and mortality fall; Conflicts of interest and guidelines; Clopidogrel patients on "inhibiting" drugs; Yale docs propose model for transparency; DES in erectile dysfunction

info@theheart.org (theheart.org) — Fri, 21 Oct 2011 14:50:00 EDT

Heart-failure hospitalizations and mortality fall; Conflicts of interest and guidelines; Clopidogrel patients on "inhibiting" drugs; Yale docs propose model for transparency; DES in erectile dysfunction

#111: Northwestern University denies tenure to Myxo ring whistleblower; Aspirin: Not for stroke prevention in AF patients; Rivaroxaban in nonvalvular AF; Dabigatran: Australia issues bleeding warning; Clopidogrel-aspirin arm halted in SPS3 stroke trial

info@theheart.org (theheart.org) — Fri, 14 Oct 2011 15:45:00 EDT

Northwestern University denies tenure to Myxo ring whistleblower; Aspirin: Not for stroke prevention in AF patients; Rivaroxaban in nonvalvular AF; Dabigatran: Australia issues bleeding warning; Clopidogrel-aspirin arm halted in SPS3 stroke trial

#110: ATLAS-2 on rivaroxaban in ACS; Same-day discharge after elective PCI; Treating clopidogrel hypersensitivity with steroids; Lowering LDL to below 70; Statin costs: brand-name vs generic

info@theheart.org (theheart.org) — Fri, 07 Oct 2011 10:50:00 EDT

ATLAS-2 on rivaroxaban in ACS; Same-day discharge after elective PCI safe; Treating clopidogrel hypersensitivity with steroids; Lowering LDL to below 70; Statin costs: brand-name vs generic

#41: The ISCHEMIA trial on optimal care for patients with stable coronary disease with Dr Judith Hochman

info@theheart.org (theheart.org) — Thu, 06 Oct 2011 10:20:00 EDT

The large ISCHEMIA trial, led by Dr Judith Hochman, seeks to build on the results of COURAGE and BARI 2D to answer the important question: what is the best treatment for patients with stable coronary disease?

#9: Behind the scenes of hospital ranking

info@theheart.org (theheart.org) — Tue, 04 Oct 2011 15:50:00 EDT

What constitutes a "top hospital"? Drs Eric Topol and Paul Teirstein review the notion of hospital ranking and the criteria used to select "top hospitals" in the renowned US News and World Report listing, the recent Joint Commission annual report, and the

#109: EMA recommends restricting dronedarone; new European recommendations for rivaroxaban; more on possible ARB-lung cancer risk; "verbal-suggestion" placebo reduces chest pain, constricts arteries; CT predictive value gender differences

info@theheart.org (theheart.org) — Thu, 29 Sep 2011 14:10:00 EDT

EMA recommends restricting dronedarone; new European recommendations for rivaroxaban; more on possible ARB-lung cancer risk; "verbal-suggestion" placebo reduces chest pain, constricts arteries; CT predictive value gender differences

#108: Statin decisions in new-onset diabetes; possible rivaroxaban antidote; elective LVAD in advanced HF?; twice-daily aspirin: better platelet inhibition in diabetics; acute-HF early-warning system implant surprises

info@theheart.org (theheart.org) — Fri, 23 Sep 2011 14:55:00 EDT

Statin decisions in new-onset diabetes; possible rivaroxaban antidote; elective LVAD in advanced HF?; twice-daily aspirin: better platelet inhibition in diabetics; acute-HF early-warning system implant surprises

#107: RITA better than radial artery for CABG; CV safety of diabetes drugs; gene studies great help for understanding hypertension; high-sensitivity troponin test rules out MI; SAMMPRIS: Meds alone beat stenting for intracranial stenosis

info@theheart.org (theheart.org) — Fri, 16 Sep 2011 16:05:00 EDT

RITA better than radial artery for CABG; CV safety of diabetes drugs; gene studies great help for understanding hypertension; high-sensitivity troponin test rules out MI; SAMMPRIS: Meds alone beat stenting for intracranial stenosis

#40: The civility of professional discourse with Dr Clyde Yancy

info@theheart.org (theheart.org) — Mon, 12 Sep 2011 14:15:00 EDT

With the multiplication of methods of communication, the democratization of access to information, and the fast pace of today's technology it's hard not to feel that professional discourse has taken a bashing and that civility in discourse is a lost art.

#106: Rivaroxaban for stroke prevention in AF: Thumbs-up from panel; SATURN: Tie rosuvastatin-atorvastatin; New ESC ACS guidelines; RUBY-1 on factor Xa inhibition in ACS; GRAVITAS: Platelet reactivity correlates with adverse events

info@theheart.org (theheart.org) — Fri, 09 Sep 2011 16:00:00 EDT

Rivaroxaban for stroke prevention in AF: Thumbs-up from panel; SATURN: Tie rosuvastatin-atorvastatin; New ESC ACS guidelines; RUBY-1 on factor Xa inhibition in ACS; GRAVITAS: Platelet reactivity correlates with adverse events

#105: Apixaban shines in ARISTOTLE; Dalcetrapib in dal-VESSEL; Oxygen for MI; clopidogrel in PRODIGY; triglycerides in Cream and Sugar Study

info@theheart.org (theheart.org) — Fri, 02 Sep 2011 17:05:00 EDT

Apixaban shines in ARISTOTLE; Dalcetrapib in dal-VESSEL; Oxygen for MI; clopidogrel in PRODIGY; triglycerides in Cream and Sugar Study

#104: What will be hot at ESC; MESA JUPITER on CAC; High marks for novel LVEF-boosting agent; Dronedarone "dear doctor" letter; Rise in ICD and pacemaker infections

info@theheart.org (theheart.org) — Fri, 26 Aug 2011 09:10:00 EDT

What will be hot at ESC; MESA JUPITER on CAC; High marks for novel LVEF-boosting agent; Dronedarone "dear doctor" letter; Rise in ICD and pacemaker infections

#103: Malpractice suits in cardiology; Unnecessary stenting: Hospital pays $1.8 million; NICE HF guideline: Difficult questions; ROCKET-AF published; Cancer vs CV disease: Money

info@theheart.org (theheart.org) — Fri, 19 Aug 2011 15:40:00 EDT

Malpractice suits in cardiology; Unnecessary stenting: Hospital pays $1.8 million; NICE HF guideline: Difficult questions; ROCKET-AF published; Cancer vs CV disease: Money

#102: Caution with dabigatran in the elderly; drugs, money, glory: is cancer beating CV disease?; multivessel PCI during STEMI; Pfizer wants Lipitor sold OTC; silent-embolization concerns with RF ablation catheter

info@theheart.org (theheart.org) — Fri, 12 Aug 2011 16:30:00 EDT

Caution with dabigatran in the elderly; drugs, money, glory: is cancer beating CV disease?; multivessel PCI during STEMI; Pfizer wants Lipitor sold OTC; silent-embolization concerns with RF ablation catheter

#39: The uptake of clinical trial findings: Focus on OAT with Dr David Kandzari

info@theheart.org (theheart.org) — Wed, 10 Aug 2011 15:25:00 EDT

Recent reports indicate that the Occluded Arteries Trial (OAT)—while continuing to stir debate—has made little impact on clinical practice among US physicians. What explains this situation?

#101: Cochrane salt/BP message blasted; US on "triple-therapy" for AF patients with stents; RE-MEDY on dabigatran vs warfarin for VTE; benefits of exercise on CHD risk; statins and stroke of unknown cause

info@theheart.org (theheart.org) — Fri, 05 Aug 2011 14:30:00 EDT

Cochrane salt/BP message blasted; US on "triple-therapy" for AF patients with stents; RE-MEDY on dabigatran vs warfarin for VTE; benefits of exercise on CHD risk; statins and stroke of unknown cause

#100: PALLAS: Deaths doubled with dronedarone; fraud conviction for John McLean; high platelet reactivity with prasugrel; APPRAISE-2 on apixaban; all about cardiac rehabilitation

info@theheart.org (theheart.org) — Fri, 29 Jul 2011 16:25:00 EDT

PALLAS: Deaths doubled with dronedarone; fraud conviction for John McLean; high platelet reactivity with prasugrel; APPRAISE-2 on apixaban; all about cardiac rehabilitation

#99: Green light for TAVI device from FDA advisors; ticagrelor approved for US market; chronic NSAID use doubles CV deaths in elderly; Parsemus Foundation on appropriate PCI; nuclear cardiology reports frequently omit information

info@theheart.org (theheart.org) — Fri, 22 Jul 2011 14:10:00 EDT

Green light for TAVI device from FDA advisors; ticagrelor approved for US market; chronic NSAID use doubles CV deaths in elderly; Parsemus Foundation on appropriate PCI; nuclear cardiology reports frequently omit information

#98: Mark Midei's medical license revoked; bleeding consensus and new definition; OAT, guidelines, and late PCI; nesiritide ASCEND-HF now in print; EMA adds CV events to review of dronedarone

info@theheart.org (theheart.org) — Fri, 15 Jul 2011 15:50:00 EDT

Mark Midei's medical license revoked; bleeding consensus and new definition; OAT, guidelines, and late PCI; nesiritide ASCEND-HF now in print; EMA adds CV events to review of dronedarone